Join us on April 16 as we explore pioneering salts and polymorphs shaping the future of psychedelic therapeutics with expert speaker, Dr. Sam Clark, CEO and Founder of Terran Biosciences.

This webinar explores a highly sensitive, automated assay workflow to provide high-quality results for low-abundance biomarkers in serum, plasma and cerebrospinal fluid.

Alzheimer’s disease (AD) is the most common form of dementia in the elderly population. While several peptide and protein biomarkers in cerebrospinal fluid (CSF) have been used for AD diagnosis, an unequivocal diagnosis in the early phases of AD is still lacking.

Join Dr. Reichelt on December 14 for this exclusive webinar which will explore the neurobiology of psychedelics, emphasizing their role in promoting neuroplasticity.

This exclusive Q&A event invites you to ask anything about the world of predatory conferences to our expert speaker.

In this webinar, our speaker will discuss the role of glucosyl and galactosyl ceramides as biomarkers and how their misregulation can be an identifier for various disease states including, but not limited to, Parkinson’s, Krabbe and Gaucher diseases.